EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease

Zhaowei Zhang iD, Shenjue Chen, Xuchun Xu, Guangwen Luo, Jian Huang

Journal of Cardiovascular Pharmacology and Therapeutics · 2024

DOI: 10.1177/10742484241265337 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, 2024. Verfasst von Zhaowei Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China. Hauptthemen laut MEDLINE: Aminobutyrates, Valsartan, Biphenyl Compounds, Drug Combinations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jinhua Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: The efficacy and safety of a lower target dose of sacubitril/valsartan (angiotensin receptor neprilysin inhibitor [ARNI]) for treating heart failure with reduced ejection fraction (HFrEF) in Chinese patients with moderate-to-severe chronic kidney disease (CKD) remain unknown. We performed a retrospective study to compare the efficacy of ARNI with that of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in patients with HFrEF and moderate-to-severe CKD.

Methods

This retrospective study included 129 patients. An inverse probability of treatment weighting (IPTW) analysis was performed to compare the baseline characteristics and outcomes between the 2 groups. The incidence of death due to cardiovascular disease, rehospitalization due to heart failure after treatment, and improvement in cardiac function symptoms (New York Heart Association [NYHA]) were assessed after 12 months. Improvements of ejection fraction (EF), N-terminal pro-brain natriuretic peptide (NT-proBNP) level, left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD) were compared.

Results

Compared with the ACEI/ARB group, the ARNI group, with 90.77% (59/65) in the lower target dose group, showed a lower rate of death due to cardiovascular disease (6.6% vs 0.9% after IPTW) and a lower incidence of rehospitalization (46.5% vs 30.4% after IPTW). NYHA class, estimated glomerular filtration rate, EF, NT-ProBNP levels, LVEDD, and LVESD improved in the ARNI group. None of the patients withdrew from treatment because of adverse drug reactions.

Conclusion

Our study showed that ARNI resulted in a greater improvement in heart failure than ACEIs/ARBs in patients with HFrEF and moderate-to-severe CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesValsartanBiphenyl CompoundsDrug CombinationsStroke VolumeRenal Insufficiency, ChronicHeart FailureAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsVentricular Function, LeftNeprilysinHumansMaleFemaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeSeverity of Illness IndexTetrazolesPatient ReadmissionTime FactorsAngiotensin II Type 1 Receptor BlockersNatriuretic Peptide, BrainChinaRecovery of FunctionPeptide Fragments

Stichwörter der Autor:innen

angiotensin receptor blockersangiotensin-converting enzyme inhibitorschronic kidney diseaseheart failuresacubitril/valsartan (LCZ696)

Substanzen

AminobutyratesValsartanBiphenyl Compoundssacubitril and valsartan sodium hydrate drug combinationDrug CombinationsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsNeprilysinTetrazolesAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
  • Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.
  • Department of Nephrology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.

ORCID-Profile: Zhaowei Zhang

Förderung

  • Jinhua Science and Technology Bureau

Zitieren

APA

Zhang, Z., Chen, S., Xu, X., Luo, G., & Huang, J. (2024). Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/10742484241265337

Vancouver

Zhang Z, Chen S, Xu X, Luo G, Huang J. Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease. Journal of Cardiovascular Pharmacology and Therapeutics. 2024. doi:10.1177/10742484241265337

BibTeX
@article{Zhang2024,
  author = {Zhang, Zhaowei and Chen, Shenjue and Xu, Xuchun and Luo, Guangwen and Huang, Jian},
  title = {Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease},
  journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.1177/10742484241265337}
}
Kostenlos starten →